Citadel Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $615K | Buy |
42,500
+21,900
| +106% | +$314K | ﹤0.01% | 8787 |
|
|
2025
Q4 | $293K | Sell |
20,600
-3,800
| -16% | -$37.3K | ﹤0.01% | 10205 |
|
|
2025
Q3 | $192K | Sell |
24,400
-5,800
| -19% | -$41.3K | ﹤0.01% | 11299 |
|
|
2025
Q2 | $173K | Buy |
30,200
+10,800
| +56% | +$69.7K | ﹤0.01% | 10819 |
|
|
2025
Q1 | $158K | Sell |
19,400
-2,200
| -10% | -$20.4K | ﹤0.01% | 10789 |
|
|
2024
Q4 | $203K | Sell |
21,600
-27,000
| -56% | -$281K | ﹤0.01% | 10430 |
|
|
2024
Q3 | $519K | Buy |
48,600
+24,900
| +105% | +$271K | ﹤0.01% | 8185 |
|
|
2024
Q2 | $235K | Sell |
23,700
-1,000
| -4% | -$10.3K | ﹤0.01% | 9598 |
|
|
2024
Q1 | $291K | Sell |
24,700
-5,200
| -17% | -$66.5K | ﹤0.01% | 9504 |
|
|
2023
Q4 | $424K | Sell |
29,900
-18,100
| -38% | -$206K | ﹤0.01% | 8451 |
|
|
2023
Q3 | $584K | Buy |
48,000
+16,400
| +52% | +$212K | ﹤0.01% | 7722 |
|
|
2023
Q2 | $397K | Sell |
31,600
-4,100
| -11% | -$48.7K | ﹤0.01% | 8426 |
|
|
2023
Q1 | $396K | Sell |
35,700
-65,300
| -65% | -$805K | ﹤0.01% | 8795 |
|
|
2022
Q4 | $1.23M | Buy |
101,000
+61,100
| +153% | +$688K | ﹤0.01% | 6408 |
|
|
2022
Q3 | $417K | Sell |
39,900
-4,500
| -10% | -$50.1K | ﹤0.01% | 8864 |
|
|
2022
Q2 | $477K | Buy |
44,400
+14,000
| +46% | +$115K | ﹤0.01% | 8750 |
|
|
2022
Q1 | $288K | Sell |
30,400
-55,100
| -64% | -$517K | ﹤0.01% | 10685 |
|
|
2021
Q4 | $988K | Sell |
85,500
-24,600
| -22% | -$274K | ﹤0.01% | 7988 |
|
|
2021
Q3 | $1.05M | Buy |
110,100
+22,900
| +26% | +$234K | ﹤0.01% | 8028 |
|
|
2021
Q2 | $841K | Sell |
87,200
-209,000
| -71% | -$2.04M | ﹤0.01% | 8797 |
|
|
2021
Q1 | $2.93M | Buy |
296,200
+188,500
| +175% | +$2.92M | ﹤0.01% | 5507 |
|
|
2020
Q4 | $2.49M | Buy |
107,700
+41,600
| +63% | +$851K | ﹤0.01% | 4903 |
|
|
2020
Q3 | $933K | Sell |
66,100
-104,800
| -61% | -$1.53M | ﹤0.01% | 6158 |
|
|
2020
Q2 | $2.58M | Buy |
170,900
+72,500
| +74% | +$883K | ﹤0.01% | 4124 |
|
|
2020
Q1 | $909K | Buy |
98,400
+34,100
| +53% | +$324K | ﹤0.01% | 5514 |
|
|
2019
Q4 | $626K | Sell |
64,300
-2,500
| -4% | -$22.9K | ﹤0.01% | 6444 |
|
|
2019
Q3 | $536K | Sell |
66,800
-13,800
| -17% | -$150K | ﹤0.01% | 6616 |
|
|
2019
Q2 | $1.01M | Buy |
80,600
+33,000
| +69% | +$419K | ﹤0.01% | 5691 |
|
|
2019
Q1 | $647K | Sell |
47,600
-14,600
| -23% | -$178K | ﹤0.01% | 6355 |
|
|
2018
Q4 | $596K | Sell |
62,200
-116,500
| -65% | -$1.28M | ﹤0.01% | 6135 |
|
|
2018
Q3 | $2.16M | Buy |
178,700
+52,600
| +42% | +$736K | ﹤0.01% | 4278 |
|
|
2018
Q2 | $1.97M | Buy |
126,100
+39,300
| +45% | +$594K | ﹤0.01% | 4140 |
|
|
2018
Q1 | $1.3M | Buy |
86,800
+28,300
| +48% | +$431K | ﹤0.01% | 4400 |
|
|
2017
Q4 | $842K | Buy |
58,500
+7,500
| +15% | +$103K | ﹤0.01% | 4901 |
|
|
2017
Q3 | $769K | Buy |
51,000
+21,900
| +75% | +$290K | ﹤0.01% | 4689 |
|
|
2017
Q2 | $293K | Sell |
29,100
-1,000
| -3% | -$8.05K | ﹤0.01% | 5953 |
|
|
2017
Q1 | $215K | Sell |
30,100
-18,900
| -39% | -$119K | ﹤0.01% | 6398 |
|
|
2016
Q4 | $244K | Buy |
49,000
+20,900
| +74% | +$145K | ﹤0.01% | 5983 |
|
|
2016
Q3 | $208K | Buy |
28,100
+11,400
| +68% | +$77K | ﹤0.01% | 6249 |
|
|
2016
Q2 | $91K | Sell |
16,700
-6,600
| -28% | -$46.2K | ﹤0.01% | 6233 |
|
|
2016
Q1 | $197K | Buy |
23,300
+12,300
| +112% | +$87.1K | ﹤0.01% | 5650 |
|
|
2015
Q4 | $107K | Sell |
11,000
-7,200
| -40% | -$64.9K | ﹤0.01% | 6606 |
|
|
2015
Q3 | $255K | Buy |
18,200
+6,700
| +58% | +$105K | ﹤0.01% | 5796 |
|
|
2015
Q2 | $163K | Buy |
11,500
+1,200
| +12% | +$14.4K | ﹤0.01% | 6567 |
|
|
2015
Q1 | $112K | Buy |
10,300
+3,700
| +56% | +$32.6K | ﹤0.01% | 6750 |
|
|
2014
Q4 | $55K | Sell |
6,600
-5,100
| -44% | -$35K | ﹤0.01% | 7121 |
|
|
2014
Q3 | $70K | Buy |
+11,700
| New | +$61.3K | ﹤0.01% | 6668 |
|
|
2014
Q1 | – | Sell |
-1,700
| Closed | -$4K | – | 7888 |
|
|
2013
Q4 | $4K | Sell |
1,700
-5,800
| -77% | -$12.7K | ﹤0.01% | 6845 |
|
|
2013
Q3 | $17K | Buy |
7,500
+3,800
| +103% | +$9.54K | ﹤0.01% | 6301 |
|
|
2013
Q2 | $9K | Buy |
+3,700
| New | +$11.4K | ﹤0.01% | 6260 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Citadel Advisors's FOLD Position: Q1 2026 in Review
Citadel Advisors reduced its Amicus Therapeutics (FOLD) stake by 98% in Q1 2026, selling an estimated $71.3M and leaving 124,794 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #6294.
Citadel Advisors first reported a position in FOLD in Q2 2013 and has held it in 48 quarters since. The position peaked at $87.5M in Q1 2019. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Citadel Advisors held 124,794 shares of Amicus Therapeutics worth $1.8M as of Q1 2026.
- Citadel Advisors sold 4,972,002 Amicus Therapeutics shares in Q1 2026, an estimated $71.3M.
- Amicus Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6294 holding.
- Citadel Advisors first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 48 quarters since.
- Citadel Advisors's Amicus Therapeutics position peaked at $87.5M in Q1 2019.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.